chronic graft-versus-host disease
Haematology · 2022–2022
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ruxolitinib Treatment of patients aged 12 years and older with moderate to severe chronic graft-versus-host disease (cGVHD) who are steroid refractory, dependent or… | Nov 2022 | Recommended with restriction | input received Leukaemia Foundation · Rare Cancers Australia · Eastern Cooperative Oncology Group |
Who spoke
Leukaemia Foundation · Rare Cancers Australia · Eastern Cooperative Oncology Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.